Stock Track | Cardinal Health Soars 5.35% Intraday on Strong Q2 Earnings Beat and Raised Guidance

Stock Track

Feb 05

Cardinal Health's stock surged 5.35% during intraday trading on Thursday, following the release of its fiscal second-quarter 2026 results that significantly exceeded analyst expectations.

The pharmaceutical distributor reported adjusted earnings per share of $2.63, beating the consensus estimate of $2.36. Quarterly revenue reached $65.6 billion, surpassing expectations of $64.14 billion and representing a 19% year-over-year increase. The company's pharmaceutical and specialty solutions segment was a key driver, with revenue jumping 19% to $60.7 billion due to strong brand and specialty pharmaceutical sales growth.

Cardinal Health also raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, up from its previous outlook. Analysts attribute the strong performance to robust demand for high-margin specialty medicines that treat complex conditions like cancer and autoimmune diseases, positioning the company for continued growth in the specialty drug market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1168655538"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168655538\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168655538?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168655538","market":"nz","top_or_hot":-1,"title":"Stock Track | Cardinal Health Soars 5.35% Intraday on Strong Q2 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>Cardinal Health's stock surged 5.35% during intraday trading on Thursday, following the release of its fiscal second-quarter 2026 results that significantly exceeded analyst expectations.</p><p>The pharmaceutical distributor reported adjusted earnings per share of $2.63, beating the consensus estimate of $2.36. Quarterly revenue reached $65.6 billion, surpassing expectations of $64.14 billion and representing a 19% year-over-year increase. The company's pharmaceutical and specialty solutions segment was a key driver, with revenue jumping 19% to $60.7 billion due to strong brand and specialty pharmaceutical sales growth.</p><p>Cardinal Health also raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, up from its previous outlook. Analysts attribute the strong performance to robust demand for high-margin specialty medicines that treat complex conditions like cancer and autoimmune diseases, positioning the company for continued growth in the specialty drug market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cardinal Health Soars 5.35% Intraday on Strong Q2 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cardinal Health Soars 5.35% Intraday on Strong Q2 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-05 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cardinal Health's stock surged 5.35% during intraday trading on Thursday, following the release of its fiscal second-quarter 2026 results that significantly exceeded analyst expectations.</p><p>The pharmaceutical distributor reported adjusted earnings per share of $2.63, beating the consensus estimate of $2.36. Quarterly revenue reached $65.6 billion, surpassing expectations of $64.14 billion and representing a 19% year-over-year increase. The company's pharmaceutical and specialty solutions segment was a key driver, with revenue jumping 19% to $60.7 billion due to strong brand and specialty pharmaceutical sales growth.</p><p>Cardinal Health also raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, up from its previous outlook. Analysts attribute the strong performance to robust demand for high-margin specialty medicines that treat complex conditions like cancer and autoimmune diseases, positioning the company for continued growth in the specialty drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAH","symbol_name":"卡地纳健康","start_time":0,"source_url":"","article_id":"1168655538","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168655538","pubTimestamp":1770302442,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Cardinal Health's stock surged 5.35% during intraday trading on Thursday, following the release of its fiscal second-quarter 2026 results that significantly exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAH":"卡地纳健康"},"translate_title":"个股追踪|康德乐盘中大涨5.35%Q2盈利强劲超预期并上调指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAH":1},"content_text":"Cardinal Health's stock surged 5.35% during intraday trading on Thursday, following the release of its fiscal second-quarter 2026 results that significantly exceeded analyst expectations.The pharmaceutical distributor reported adjusted earnings per share of $2.63, beating the consensus estimate of $2.36. Quarterly revenue reached $65.6 billion, surpassing expectations of $64.14 billion and representing a 19% year-over-year increase. The company's pharmaceutical and specialty solutions segment was a key driver, with revenue jumping 19% to $60.7 billion due to strong brand and specialty pharmaceutical sales growth.Cardinal Health also raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, up from its previous outlook. Analysts attribute the strong performance to robust demand for high-margin specialty medicines that treat complex conditions like cancer and autoimmune diseases, positioning the company for continued growth in the specialty drug market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}